诊断后3个月和6个月的疾病活动度对ANCA相关性血管炎长期结局的影响
本研究基于4项欧洲血管炎学会ANCA相关性血管炎初始临床试验(1995-2002)及其长期随访数据,分析354例患者诊断后3个月和6个月的疾病状态与死亡及终末期肾衰竭(ESRF)风险的关系。中位随访5.7年,结果显示6个月时晚缓解、复发和难治性疾病均与死亡或ESRF复合终点风险升高独立相关,提示早期疾病控制可作为诱导缓解试验的终点。
要点
- 6个月时晚缓解、复发和难治性疾病与死亡或ESRF风险升高相关。
- 年龄、基线eGFR和6个月疾病状态是复合终点的独立预测因素。
- 诊断后3个月和6个月的疾病状态可能作为AAV诱导试验的有效终点。
核心结论
- 诊断后3个月和6个月的疾病状态可能预测AAV患者长期死亡和ESRF风险。
- 早期疾病控制可作为未来AAV诱导缓解临床试验的有效终点。
- 当前发现需在更大数据集验证。
研究设计与样本
- 基于4项欧洲血管炎学会ANCA相关性血管炎初始临床试验(1995-2002)及其长期结局登记数据。
- 共纳入354例AAV患者,中位随访5.7年。
- 评估基线及诊断后3、6个月临床参数与长期死亡和ESRF风险的关系。
主要发现
- 354例患者中46例(13%)发生ESRF,66例(18.6%)死亡,89例(25.1%)死亡或发生ESRF。
- 6个月时复合终点预测因素:年龄HR 1.02(95%CI 1-1.05,P=0.012)。
- 6个月时复合终点预测因素:eGFR HR 0.94(95%CI 0.92-0.95,P<0.001)。
- 6个月时疾病状态预测复合终点:晚缓解HR 2.94(95%CI 1.1-7.85,P=0.031)。
- 6个月时疾病状态预测复合终点:复发HR 8.21(95%CI 2.73-24.65,P<0.001);难治HR 4.89(95%CI 1.96-12.18,P=0.001)。
关键数值与推荐
- 6个月时疾病状态定义:持续缓解为3个月内缓解并持续至6个月。
- 晚缓解为3个月后至6个月内缓解;复发为3个月内缓解但6个月内复发;难治为6个月内未缓解。
临床怎么用
- 对AAV患者应密切监测诊断后3个月和6个月的疾病活动度,以实现早期疾病控制。
- 6个月时达到持续缓解可能降低长期死亡和ESRF风险。
- 早期疾病状态可作为临床试验终点,但需更大数据集验证。
局限性
- 研究基于1995-2002年临床试验数据,结论需在更大数据集中验证。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The treatment of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) aims to suppress disease activity and prevent subsequent disease flare. This study sought to explore the association of early disease control with long-term outcomes to validate early disease control as an end point for future clinical trials in AAV. METHODS: Data from 4 European Vasculitis Society inception clinical trials in AAV (1995-2002) and subsequent data on long-term outcomes from the trial data registry were studied. Clinical parameters in patients with AAV at baseline and at 3 and 6 months after diagnosis were assessed to study the long-term risk of death and end-stage renal failure (ESRF). At 6 months, outcomes were defined based on a disease status of either sustained remission (remission by 3 months, sustained to 6 months), late remission (remission after 3 months and by 6 months), relapsing disease (remission by 3 months but relapse by 6 months), or refractory disease (no remission by 6 months). RESULTS: Of the 354 patients with AAV who were followed up for a median of 5.7 years, 46 (13%) developed ESRF, 66 (18.6%) died, and 89 (25.1%) had either died or developed ESRF. At 6 months, predictors of the composite end point of death or ESRF were as follows: age (hazard ratio [HR] 1.02, 95% confidence interval [95% CI] 1-1.05; P = 0.012), estimated glomerular filtration rate (HR 0.94, 95% CI 0.92-0.95; P < 0.001), and disease status at 6 months (late remission, HR 2.94, 95% CI 1.1-7.85 [P = 0.031]; relapsing disease, HR 8.21, 95% CI 2.73-24.65 [P < 0.001]; refractory disease, HR 4.89, 95% CI 1.96-12.18 [P = 0.001]). Similar results were observed when these analyses were performed separately for death and for ESRF. CONCLUSION: The results of this study suggest that disease status at 3 and 6 months following the diagnosis of AAV may be predictive of the long-term risk of mortality and ESRF, and therefore these may be valid end points for induction trials in AAV. The current findings need to be validated in a larger data set.
引用
- Gopaluni S, Flossmann O, Little MA, et al. Effect of Disease Activity at Three and Six Months After Diagnosis on Long-Term Outcomes in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis Rheumatol. 2019. PMID: 30418705. doi:10.1002/art.40776
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。